Related Experiment Video

Updated: Jun 21, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Symptomatic and pathophysiologic predictors of hepatitis C virus progression in pediatric patients

Wendy A Henderson1, Ravi Shankar, Jordan J Feld

  • 1Biobehavioral Unit, Symptoms Management Branch, Intramural Research Program, National Institute of Nursing Research, National Institutes of Health, Bethesda, MD 20892, USA. hendersw@mail.nih.gov

The Pediatric Infectious Disease Journal
|July 14, 2009
PubMed

Insights

Pediatric hepatitis C virus (HCV) infection often presents with symptoms and liver changes. Lower viral loads were linked to more symptoms in children with HCV.

Area of Science:

  • Pediatric Hepatology
  • Viral Hepatitis
  • Clinical Research

Background:

  • Hepatitis C virus (HCV) infection poses long-term health risks for children.
  • Understanding HCV's presentation in pediatric populations is crucial for effective management.

Purpose of the Study:

  • To describe the symptomatic and pathophysiologic features of HCV infection in pediatric outpatients.
  • To analyze demographic and clinical indicators associated with HCV in children.

Main Methods:

  • Retrospective analysis of HCV-positive pediatric outpatients (3 months to 19 years).
  • Data collected included demographics, symptoms, liver function tests, viral load, genotype, and liver biopsy results.
  • Statistical analysis to identify relationships between variables and symptom status.

Main Results:

  • 62 pediatric patients reviewed; 60% exhibited symptoms like fatigue or pain.
  • Liver biopsies revealed inflammation (80%), fibrosis (57%), and steatosis (9%).
  • Symptomatic patients were older, more likely male, and had lower viral loads.

Conclusions:

  • Pediatric HCV infection can manifest with notable symptoms and significant liver pathology.
  • Early identification and management are essential for mitigating long-term impacts.
Abstract

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...